晚期卵巢癌经TP联合腹腔热灌注化疗后临床疗效及CEA、CA125变化分析  

Analysis of clinical efficacy and changes of CEA and CA125 in advanced ovarian cancer after TP combined with intraperitoneal hyperthermic perfusion chemotherapy

作　　者：陈艳惠 郭丽娜 祝欣 黄丽玲[1] 张兰[1] CHEN Yanhui;GUO Lina;ZHU Xin;HUANG Liling;ZHANG Lan(Department of Obstetrics and Gynecology,No.909 Hospital of Joint Logistics Support Force/Southeast Hospital Affiliated to Xiamen University,Zhangzhou,Fujian,China,363000)

机构地区：[1]联勤保障部队第九〇九医院/厦门大学附属东南医院妇产科,福建漳州363000

出　　处：《分子诊断与治疗杂志》2022年第7期1225-1228,共4页Journal of Molecular Diagnostics and Therapy

基　　金：福建省自然科学基金面上项目(2017J01152)。

摘　　要：目的分析晚期卵巢癌经紫杉醇与顺铂联合化疗方案(TP)联合腹腔热灌注化疗后临床疗效及CEA、CA125变化。方法收集2016年2月至2021年2月联勤保障部队第九〇九医院收治的106例晚期卵巢癌患者,其中49例为TP治疗(对照组),57例为TP+IHPC治疗(观察组)。比较两组临床疗效、卡氏评分(KPS)、癌胚抗原(CEA)、糖类抗原125(CA125)、免疫指标(CD3+、CD4+、CD8+、CD4+/CD8+)、毒副反应。结果观察组治疗后有效率、疾病控制率分别为57.89%、89.47%,明显高于对照组的38.77%、69.39%,差异有统计学意义(P<0.05)。治疗前两组KPS评分及CEA、CA125水平比较差异无统计学意义(P>0.05),治疗后KPS评分明显升高,CEA、CA125水平降低,且观察组治疗后KPS评分高于对照组,CEA、CA125水平低于对照组,差异均有统计学意义(P<0.05)。治疗前两组免疫功能各指标比较差异无统计学意义(P>0.05),治疗后CD3+、CD4+、CD4+/CD8值均提升,CD8+值降低,且观察组治疗后CD3+、CD4+、CD4+/CD8明显高于对照组,CD8+低于对照组,差异均有统计学意义(P<0.05)。两组的毒副反应比较比较差异无统计学意义(P>0.05)。结论IHPC+TP治疗晚期卵巢癌患者临床疗效佳,可降低CA125、CEA表达水平,提升患者生活质量,安全性尚可。Objective To analyze the clinical efficacy and changes of CEA and CA125 in advanced ovarian cancer after paclitaxel and cisplatin combined chemotherapy(TP)combined with intraperitoneal hyperthermic perfusion chemotherapy(IHPC). Methods 106 patients with advanced ovarian cancer who were admitted to our hospital from February 2016 to February 2021 were collected,of which 49 were treated with TP(control group)and 57 were treated with TP+IHPC(observation group). The clinical efficacy,Kaplan score(KPS),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),immune index(CD3+,CD4+,CD8+,CD4+/CD8+)and toxic side effects between the two groups were compared.Results After treatment,the effective rate and disease control rate in the observation group were 57.89% and89.47%,which were significantly higher than those in the control group(38.77%,69.39%),and the difference was statistically significant(P<0.05). There was no significant difference in KPS score,CEA and CA125 levels between the two groups before treatment(P>0.05). After treatment,the KPS score was significantly increased,while the levels of CEA and CA125 were decreased. After treatment,the KPS score of the observation group was higher than that of the control group,and the levels of CEA and CA125 were lower than those of the control group,the difference was statistically significant(P<0.05). Before treatment,there was no significant difference in the indicators of immune function between the two groups(P>0.05). After treatment,CD3+,CD4+,CD4+/CD8 were significantly higher than those in the control group,and CD8+was lower than that in the control group,and the difference was statistically significant(P<0.05). Conclusion IHPC + TP has good clinical efficacy in the treatment of advanced ovarian cancer patients. It can reduce the levels of CA125,CEA,and improves the quality of life of patients,with acceptable safety.

关 键 词：晚期卵巢癌 TP 腹腔热灌注化疗 KPS评分 CEA CA125 

分 类 号：R737.31[医药卫生—肿瘤]